Page 83 - Read Online

Page 34 Pandey et al. J Transl Genet Genom 2021;5:22-36 I http://dx.doi.org/10.20517/jtgg.2020.45

Availability of data and materials
Not applicable.

Financial support and sponsorship
Pandey A received financial support from Davidson School of Chemical Engineering, Purdue University.

Conflicts of interest
Estepp JH receives research funding support from Global Blood Therapeutics, Forma Therapeutics, Pfizer,
and Eli Lilly and Co. Estepp JH provides consultancy to Daiichi Sankyo, Esperion, and Global Blood
Therapeutics. Estepp JH also receives research funding support from American Society of Hematology
(ASH) and National Heart, Lung, and Blood Institute (NHLBI). The other authors declare no conflicts of
interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea
treatment for sickle cell disease. Ann Intern Med 2008;148:932-8.
2. Bunn, HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-9.
3. Steinberg, MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-30.
4. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376:2018-31.
5. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest 2007;117:850-8.Fi
6. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343-60.
7. Serjeant GR. Sickle-cell disease. Lancet 1997;350:725-30.
8. Faivre C, El Cheikh R, Barbolosi D, Barlesi F. Mathematical optimisation of the cisplatin plus etoposide combination for managing
extensive-stage small-cell lung cancer patients. Br J Cancer 2017;116:344-8.
9. Houy N, Le Grand F. Administration of temozolomide: Comparison of conventional and metronomic chemotherapy regimens. J Theor
Biol 2018;446:71-8.
10. Jayachandran D, Rundell AE, Hannemann RE, Vik TA, Ramkrishna D. Optimal chemotherapy for leukemia: a model-based strategy for
individualized treatment. PLoS One 2014;9:e109623.
11. Jayachandran D, Laínez-Aguirre J, Rundell A, et al. Model-Based Individualized Treatment of Chemotherapeutics: Bayesian Population
Modeling and Dose Optimization. PLoS One 2015;10:e0133244.
12. Ajmera I, Swat M, Laibe C, Le Novère N, Chelliah V. The impact of mathematical modeling on the understanding of diabetes and related
complications. CPT Pharmacometrics Syst Pharmacol 2013;2:e54.
13. Wodarz D, Nowak MA. Mathematical models of HIV pathogenesis and treatment. Bioessays 2002;24:1178-87.
14. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by
expert panel members. JAMA 2014;312:1033-48.
15. Telen MJ, Malik P, Vercellotti GM. Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nat Rev Drug Discov
2019;18:139-58.
16. Rai P, Ataga KI. Drug Therapies for the Management of Sickle Cell Disease. F1000Res 2020;9:592.
17. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent.
The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 1996;75:300-26.
18. Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood 2017;129:2719-26.
19. Tracewell WG, Trump DL, Vaughan WP, Smith DC, Gwilt PR. Population pharmacokinetics of hydroxyurea in cancer patients. Cancer
Chemother Pharmacol 1995;35:417-22.
20. Villani P, Maserati R, Regazzi MB, Giacchino R, Lori F. Pharmacokinetics of hydroxyurea in patients infected with human
immunodeficiency virus type I. J Clin Pharmacol 1996;36:117-21.
21. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to